Lung Cancer Academy 2022: Does molecular testing matter in NSCLC?

Join us for this unique opportunity to take a deep dive into the Lung Cancer Diagnostic Pathway

Programme overview

The effectiveness of treatment in non-small-cell lung cancer (NSCLC) depends on the accurate determination of the genomic status of the tumour. For this reason, molecular analyses to detect tumour genomic aberrations have become standard of care in patients with advanced disease, and now also in patients with early disease.

Please join us for this unique opportunity to take a deep dive into the Lung Cancer Molecular Diagnostic Pathway, with a specific focus on tumour molecular testing. We will cover how to ensure optimal tissue sampling and the tissue requirements for molecular testing as well as discussing the successes, challenges and applications of ctDNA in lung cancer diagnosis.

The day will include a unique opportunity to hear from several leading clinical scientists from two London Genomic Laboratory Hubs. They will discuss the key assays used in the genomic laboratory, and will provide a useful guide to the interpretation of an NGS report for the clinician, as well as offering an exclusive insider view on the benefits and challenges of the recent changes to genomic testing services across the UK.

Finally the information learnt will be brought together in a number of illustrated case presentations and discussions led by two lung cancer medical oncologists.

Who should attend?

Junior to intermediate level clinicians as well as consultants in oncology and respiratory medicine. Other healthcare professionals within the lung cancer multidisciplinary team.

Agenda

Lung Cancer Academy 2022 draft agenda

09:00 – 09:30

Registration and arrival

Please go to the Robens Suite on the 29th Floor of Tower Wing, Guy’s Hospital for registration and welcome coffee

09:30 – 09:35

Welcome and agenda

  • Dr Eleni Karapanagiotou, Guy’s and St Thomas’ NHS Foundation Trust
  • Dr Debra Josephs, Guy’s and St Thomas’ NHS Foundation Trust

09:35 – 10:00

Treating NSCLC; Setting the scene

  • Dr Eleni Karapanagiotou, Guy’s and St Thomas’ NHS Foundation Trust
  • Dr Debra Josephs, Guy’s and St Thomas’ NHS Foundation Trust

10:00 – 10:50

Tissue Sampling EBUS vs IR-guided procedures in NSCLC

  • Professor George Santis and IR Consultant (TBC)

10:50 – 11:00

Coffee break

11:00 – 11:30

Tissue Requirements for diagnosis

NSCLC Histological subtypes, IHC and genomic tests, challenges and pitfalls

  • Martina Munonyara, Consultant Pathologist, Guy’s and St Thomas’ NHS Foundation Trust

11:30 – 11:55

Genomic testing -Inside the Lab. Understanding the assay choices

  • Nicola Foot, Service Lead for Cancer Genetics, Consultant Clinical Scientist, Guy’s and St Thomas’ NHS Foundation Trust

11:55 – 12:20

Circulating tumour DNA- successes, challenges and applications

  • Gareth Gerrard, Clinical Scientist and Scientific Lead for Cancer Genomics (South East Genomic Laboratory Hub), Guy’s and St Thomas’ NHS Foundation Trust

12:20 – 12:45

Interpretation of an NGS report for the clinician

  • Amy Roe, Operational Lead for Cancer Genetics (South East Genomic Laboratory Hub), Guy’s and St Thomas’ NHS Foundation Trust

12:20 – 12:45

Lunch

Janssen Sponsor Symposia

14:00 – 14:30

UK Genomic Testing Landscape with focus on Lung Cancer

Changes to the system, the benefits and remaining gaps and challenges

  • Dr Philip Bennett, Principal Clinical Scientist and Service Lead
  • Sarah Cannon Molecular Diagnostics

14:30 – 15:30

Does tumour molecular profiling really matter?

Case presentations with imaging. Delegates will debate and discuss appropriate treatment options

  • Dr Eleni Karapanagiotou, Guy’s and St Thomas’ NHS Foundation Trust
  • Dr Debra Josephs, Guy’s and St Thomas’ NHS Foundation Trust

15:30

Networking and Close

How to book

Book now via Eventbrite

Sponsors